Entrada Therapeutics Inc (TRDA) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

– Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

– Additional positive data from the Company’s completed Phase 1 clinical trial evaluating ENTR-601-44...

Form 4 - Statement of changes in beneficial ownership of securities

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities